ADVA
ADVA (FSE: ADV) today announced that its FSP 150-XG480 has become the first 100Gbit/s solution on the market to achieve MEF 3.0 Carrier Ethernet certification. The compact metro edge device is now the industry’s only 100Gbit/s packet aggregation and demarcation technology proven to offer the highest available levels of performance, assurance and agility. With the ADVA FSP 150-XG480, enterprises and communication service providers (CSPs) can address the boom in cloud computing and mobile services by smoothly transitioning to 10 and 25Gbit/s service aggregation. What’s more, ADVA’s MEF 3.0-compliant technology enables them to meet the need for high-capacity wholesale, mobile and business services with a solution that supports automated networking and 5G-ready architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005017/en/
“CSPs now have the power to tackle the demand for 100Gbit/s aggregation at the metro edge with a solution guaranteed to deliver the highest industry standards for performance and assurance. With our unique technology, there’s now a simple and extremely cost-efficient route to MEF 3.0-certified 100Gbit/s service aggregation,” said James Buchanan, GM, Edge Cloud, ADVA. “Higher speeds in the access network are becoming essential. In fact, with the emergence of more and more connected devices as well as the unprecedented surge in video streaming platforms, 10Gbit/s is becoming the new 1Gbit/s. What our FSP 150-XG480 offers is a future-proof way to deliver MEF CE services up to 100Gbit/s and enable the efficient and reliable aggregation of multiple 10Gbit/s streams.”
The compact and powerful ADVA FSP 150-XG480 aggregator with high-density 1, 10 and 25Gbit/s port count is the ultimate tool for fighting bandwidth bottlenecks and evolving metro networks to 100Gbit/s. Its MEF 3.0-compliant interfaces and operation and management capabilities enable seamless integration into existing networks and established processes. The ADVA FSP 150-XG480 offers a range of advantages for connectivity and synchronization in mobile backhaul networks. These include leveraging ADVA’s Oscilloquartz Syncjack™ technology to constantly control the accuracy of network timing. It’s also the only device available with 100Gbit/s line-rate service activation and testing, so there’s no need for CSPs to compromise on high-value SLA-based business services.
“Achieving MEF 3.0-compliant status with our FSP 150-XG480 highlights the leading role ADVA continues to play in the Carrier Ethernet space. This certification is also great news for enterprises across the world as well as mobile network operators looking to meet soaring data demand. Now they can map 10 and 25GbE into 100Gbit/s aggregated bandwidth with a solution that easily expands to meet the coming requirements of 5G networks,” commented Eli Angel, VP, product line management, Ethernet access, ADVA. “Our FSP 150-XG480 is the key to future scalability. It also features an incredibly small form factor and environmentally hardened design, delivering a significant cost advantage over competing technology.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005017/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom